Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain

Blood

Volumn 90, Issue 1, 1997, Pages 260-269

  Potter, Michael ^a   Wax, Judith ^b   Jones, Gary M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PLASTIC; POLYCARBONATE; PRISTANE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL;

EID: 0030946077     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.260.260_260_269     Document Type: Article

References (67)

1. Potter M, Mushinski EB, Wax JS, Hartley J, Mock BA: Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. Cancer Res 54:1, 1994
2. Anderson PN, Potter M: Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 222:994, 1969
3. Potter M, Morrison S, Wiener F, Miller FW: Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J Natl Cancer Inst 86:1058, 1994
4. Merwin RM, Redmon LW: Induction of plasma cell tumors and sarcomas in mice by diffusion chambers placed in the peritoneal cavity. J Natl Cancer Inst 31:990, 1963
5. Muller JR, Jones GM, Janz S, Potter M: Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice. Blood 89:1997
6. Potter M, Wiener F: Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 13:1681, 1992
7. Mushinski JF: c-myc oncogene activation and chromosomal translocation in BALB/c plasmacytomas, in Klein G (ed): Cellular Oncogene Activation. New York, NY, Dekker, 1988, p 181
8. Wiener F, Potter M: Myc-associated chromosomal translocations and rearrangements in plasmacytomagenesis in mice, in Kirsch IR (ed): The Causes and Consequences of Chromosomal Aberrations. Boca Raton, FL, CRC, 1993
9. Janz S, Muller J, Shaughnessy J, Potter M: Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc Natl Acad Sci USA 90:7361, 1993
10. Muller JR, Potter M, Janz S: Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. Proc Natl Acad Sci USA 91:12066, 1994
11. Takakura K, Yamada H, Hollander VP: Studies on the pathogenesis of plasma cell tumors. II. The role of mast cells and pituitary glycoprotein hormones in the inhibition of plasma cell tumorigenesis. Cancer Res 26:2564, 1966
12. Potter M, Wax JS, Anderson AO, Nordan RP: Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J Exp Med 161:996, 1985
13. Kulmacz RJ, Lands WEM: Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 260:12572, 1985
14. Stanford N, Roth GJ, Shen TY, Majerus PW: Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Mech Indo Action 13:669, 1977
15. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228, 1994
16. Mock BA, Holiday DL, Cerretti DP, Darnell SC, O'Brien AD, Potter M: Construction of a series of congenic mice with recombinant chromosome 1 regions surrounding the genetic loci for resistance to intracellular parasites (Ity, Lsh, and Bcg), DNA repair responses (Rep-1), and the cytoskeletal protein villin (Vil). Infect Immun 62:325, 1994
17. Muller JR, Potter M, Janz S: Differences in the molecular structure of c-myc activating recombinations in murine plasmacytomas and precursor cells. Proc Natl Acad Sci USA 91:12066, 1994
18. Morse HC III, Hartley JW, Potter M: Genetic considerations in plasmacytomas of BALB/c NZB and (BALB/c x NZB)F1 mice, in Potter M (ed): Progress in Myeloma. Biology of Myeloma. North Holland, NY, Elsevier, 1980, p 263
19. Potter M, Wax JS: Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: Reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 127:1591, 1981
20. Potter M, Wax JS: Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 71:391, 1983
21. Dux K, Rouse RV, Kyewski B: Composition of the lymphoid cell populations from omental milky spots during the immune response in C57BL/Ka mice. Eur J Immunol 16:1029, 1986
22. Dux K, Janik P, Szaniawska B: Kinetics of proliferation, cell differentiation, and IgM secretion in the omental lymphoid organ of B10/Sn mice following intraperitoneal immunization with sheep erythrocytes. Cell Immunol 32:97, 1977
23. Dux K: Anatomy of the greater and lesser omentum in the mouse with some physiological implications, in Goldsmith HS (ed): The Omentum, Research and Clinical Applications. New York, NY, Springer-Verlag, 1988, p 19
24. Holub M, Polanova E: The response of omental lymphatics to antigen stimulation, in Verlag T, Hgnot S (eds): Progress in Lymphology, 1978, p 264
25. Unemori EN, Ehsani N, Wang M, Lee S, McGuire J, Amento EP: Interleukin-1 and transforming growth factor-alpha: Synergistic stimulation of metalloproteinases, PGE2, and proliferation in human fibroblasts. Exp Cell Res 210:166, 1994
26. Hinson RM, Williams JA, Shacter E: Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 93:4885, 1996
27. Brown DM, Phipps RP: Characterization and regulation of prostaglandin E2 receptors on normal and malignant murine B lymphocytes. Cell Immunol 161:79, 1995
28. Fedyk ER, Phipps RP: Prostaglindin E2 receptors of the EP2 and EP4 subtypes regulate B lymphocyte activation and differentiation to IgE-secreting cells. Proc Natl Acad Sci USA 93:10978, 1996
29. Holter W, Spiegel AM, Howard BH, Weber S, Brann MR: Expression of GTP-binding proteins and prostaglandin E2 receptors during human T cell activation. Cell Immunol 134:287, 1991
30. Coleman RA, Smith WL, Narumiya S: International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205, 1994
31. Lydyard PR, Brostoff J, Hudspith BN, Parry H: Prostaglandin E2-mediated enhancement of human plasma cell differentiation. Immunol Lett 4:113, 1982
32. Behrens TW, Goodwin JS: Control of humoral immune responses by arachidonic acid metabolites. Agents Actions 26:15, 1989
33. Jelinek DF, Thompson PA, Lipsky PE: Regulation of human B cell activation by prostaglandin E2. J Clin Invest 75:1339, 1985
34. Phipps RP, Lee D, Schad V, Warner GL: E-series prostaglandins are potent growth inhibitors for some B lymphomas. Eur J Immunol 19:996, 1989
35. Roper RL, Ludlow JW, Phipps RP: Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins. Cell Immunol 154:296, 1994
36. Novak TJ, Rothenberg EV: cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 87:9353, 1990
37. Hilkens CM, Vermeulen H, van Neerven RJ, Snijdewint FG, Wierenga EA, Kapsenherg ML: Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol 25:59, 1995
38. Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE: Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol 145:2616, 1990
39. Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Bournpas DT: Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol 148:2845, 1992
40. Katamura K, Shintaku N, Yamauchi Y, Fukui T, Ohshima Y, Mayumi M, Furusho K: Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 155:4604, 1995
41. Steeg PS, Johnson HM, Oppenheim JJ: Regulation of murine macrophage Ia antigen expression by an immune interferon-like lymphokine: inhibitory effect of endotoxin. J Immunol 129:2402, 1982
42. Snyder DS, Beller DI, Unanue ER: Prostaglandins modulate macrophage Ia expression. Nature 299:163, 1982
43. Knudsen PJ, Dinarello CA, Strom TB: Prostaglandins post-transcriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137:3189, 1986
44. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA: Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181:775, 1995
45. Hilkens CM, Snijders A, Vermeulen H, van der Meide PH, Wierenga EA, Kapsenberg ML: Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells. J Immunol 156:1722, 1996
46. Byrd LG, McDonald AH, Gold LG, Potter M: Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J Immunol 147:3632, 1991
47. McDonald AH, Degrassi A: Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice. Cell Immunol 146:157, 1993
48. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG: In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 90:2060, 1993
49. Shacter E, Arzadon GK, Williams JA: Stimulation of interleukin-6 and prostaglandin E2 secretion from peritoneal macrophages by polymers of albumin. Blood 82:2853, 1993
50. Romanova LY, Alexandrov IA, Schwab G, Hilbert DM, Mushinski JF, Nordan RP: Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle. Biochemistry 35:9900, 1996
51. Klein B: Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 32:4, 1995
52. Hibi M, Nakajima K, Hirano T: IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 74:1, 1996
53. Arkins S, Rebeiz N, Biragyn A, Reese DL, Kelley KW: Murine macrophages express abundant insulin-like growth factor-I class I Ea and Eb transcripts. Endocrinology 133:2334, 1993
54. Nam TJ, Busby WH Jr, Clemmons DR: Characterization and determination of the relative abundance of two types of insulin-like growth factor binding protein-5 proteases that are secreted by human fibroblasts. Endocrinology 137:5530, 1996
55. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3, 1995
56. Kimata H, Yoshida A: Effect of growth hormone and insulin-like growth factor-I on immunoglobulin production by and growth of human B cells. J Clin Endocr Metab 78:635, 1994
57. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88:2250, 1996
58. Kimata H, Yoshida A: Differential effect of growth hormone and insulin-like growth factor-I, insulin-like growth factor-II, and insulin on Ig production and growth in human plasma cells. Blood 83:1569, 1994
59. Freund GG, Kulas DT, Mooney RA: Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151:1811, 1993
60. Freund GG, Kulas DT, Way BA, Mooney RA: Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54:3179, 1994
61. Fournier T, Riches DW, Winston BW, Rose DM, Young SK, Noble PW, Lake FR, Henson PM: Divergence in macrophage insulin-like growth factor-I (IGF-I) synthesis induced by TNF-alpha and prostaglandin E2. J Immunol 155:2123, 1995
62. Pash JM, Canalis E: Transcriptional regulation of insulin-like growth factor-binding protein-5 by prostaglandin E2 in osteoblast cells. Endocrinology 137:2375, 1996
63. McCarthy TL, Casinghino S, Mittanck DW, Ji CH, Centrella M, Rotwein P: Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. J Biol Chem 271:6666, 1996
64. Berg DJ, Lynch RG: Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. J Immunol 146:2865, 1991
65. Weiskirch LM, Bar-Dagan Y, Mokyr MB: Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 38:215, 1994
66. Gauthier ER, Piche L, Lemieux G, Lemieux R: Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res 56:1451, 1996
67. Muller JR, Jones GM, Potter M, Janz S: Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Cancer Res 56:419, 1996